Figure 8.
IT-901 is active on primary Richter syndrome (RS) cells and in patient-derived xenograft (PDX). (A) Cumulative data of apoptosis of primary or PDX-tumor-derived RS cells. (B) Western blot analysis of the expression of the nuclear factor-kappa B (NF-κB) complex, pro- and anti-apoptotic proteins and caspase-3 in RS cells exposed to the indicated doses of IT-901 for 6 hours (h). Actin was used as loading control. (C) Tumor masses from vehicle- or IT-901-treated RS-PDX mice compared for tumor volume (cm3) and weight (g) (6 mice/group; double-flank injected). (D) Immunohistochemistry analysis of p65 expression within the tumor mass. Staining was reported as percentage of positive cells. (E) Cytoplasmic (C) and nuclear (N) fractions obtained from RS cells purified from the tumor mass were resolved by SDS-PAGE and expression of the NF-κB complex analyzed. β-tubulin and Lamin A/C were used as cytoplasmic and nuclear controls, respectively. FL: full-length; CL: cleaved.